

NDA 204684/S-007 & S-008

**SUPPLEMENT APPROVAL**

Knight Therapeutics (USA) Inc.  
c/o Fast Track Drugs and Biologics, LLC  
Attention: Bernadette Tock, MS  
Regulatory Affairs Scientist  
20010 Fisher Avenue, Suite G  
Poolesville, MD 20837

Dear Bernadette Tock:

Please refer to your supplemental new drug applications (sNDAs) dated and received September 17, 2021 (S-007), and August 24, 2023 (S-008), and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Impavido (miltefosine) capsule.

S-007: This Prior Approval sNDA provides for revisions to the following sections of the Prescribing information (PI):

**HIGHLIGHTS OF PRESCRIBING INFORMATION, RECENT MAJOR CHANGES, FULL PRESCRIBING INFORMATION CONTENTS, WARNINGS AND PRECAUTIONS (5), Ocular Complications (5.10), ADVERSE REACTIONS (6), Postmarketing Experience (6.2), Adverse Reactions from Postmarketing Spontaneous Reports, Eye Disorders subheading, and Adverse Reactions from Observational Studies, Investigations and Musculoskeletal disorders subheadings, and to **NONCLINICAL TOXICOLOGY (13), Animal Toxicology and/or Pharmacology (13.2).****

S-008: This “Changes Being Effected” sNDA provides for:

(1) updates to the contact information in the PI, **HIGHLIGHTS OF PRESCRIBING INFORMATION, ADVERSE REACTIONS**, for reporting **SUSPECTED ADVERSE REACTIONS**, (2) removal of the web address in the **USE IN SPECIFIC POPULATIONS (8), Pregnancy (8.1), Pregnancy Exposure Registry** subheading, (3) removal of the registry web address, and (4) in the Medication Guide (MG), updates to the web address and phone number for Knight.

Additionally, corresponding changes were made to the MG and editorial updates were made throughout labeling.

## **APPROVAL & LABELING**

We have completed our review of these applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

## **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.<sup>1</sup> Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information and Medication Guide), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.<sup>2</sup>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

## **PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format-Promotional Labeling and Advertising Materials for Human Prescription Drugs*.<sup>3</sup>

---

<sup>1</sup> <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

<sup>2</sup> We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

<sup>3</sup> For the most recent version of a guidance, check the FDA guidance web page at <https://www.fda.gov/media/128163/download>.

You must submit final promotional materials and Prescribing Information, accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at [FDA.gov](http://FDA.gov).<sup>4</sup> Information and Instructions for completing the form can be found at [FDA.gov](http://FDA.gov).<sup>5</sup>

[NOTE: The use of the term “new safety-related information” below includes new safety information (NSI) as described in section 505-1(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) (21 U.S.C. 355-1(b)) and other safety-related information unrelated to section 505(o)(4) of the FDCA.]

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety-related information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety-related information that appears in the revised labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4).

### **PATENT LISTING REQUIREMENTS**

Pursuant to 21 CFR 314.53(d)(2) and 314.70(f), certain changes to an approved NDA submitted in a supplement require you to submit patent information for listing in the Orange Book upon approval of the supplement. You must submit the patent information required by 21 CFR 314.53(d)(2)(i)(A) through (C) and 314.53(d)(2)(ii)(A) and (C), as applicable, to FDA on Form FDA 3542 within 30 days after the date of approval of the supplement for the patent information to be timely filed (see 21 CFR 314.53(c)(2)(ii)). You also must ensure that any changes to your approved NDA that require the submission of a request to remove patent information from the Orange Book are submitted to FDA at the time of approval of the supplement pursuant to 21 CFR 314.53(d)(2)(ii)(B) and 314.53(f)(2)(iv).

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

---

<sup>4</sup> <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>

<sup>5</sup> <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>

If you have any questions, contact Joseph Nguyen, PharmD, Regulatory Project Manager, at (301) 348-3937 or [jospheh.nguyen@fda.hhs.gov](mailto:jospheh.nguyen@fda.hhs.gov).

Sincerely,

*{See appended electronic signature page}*

Dmitri Iarikov, MD, PhD  
Deputy Director  
Division of Anti-Infectives  
Office of Infectious Diseases  
Office of New Drugs  
Center for Drug Evaluation and Research

ENCLOSURES:

- Content of Labeling
  - Prescribing Information
  - Medication Guide

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

DMITRI IARIKOV  
03/14/2025 03:54:29 PM